Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price

Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by Royal Bank Of Canada from $28.00 to $30.00 in a research report sent to investors on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

A number of other research analysts have also recently commented on NRIX. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday. Mizuho lifted their price objective on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Oppenheimer dropped their target price on shares of Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a research report on Friday, October 10th. Truist Financial started coverage on shares of Nurix Therapeutics in a report on Monday, November 24th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Nurix Therapeutics Price Performance

NRIX stock opened at $17.59 on Thursday. Nurix Therapeutics has a 1 year low of $8.18 and a 1 year high of $22.50. The company has a market cap of $1.35 billion, a P/E ratio of -5.79 and a beta of 1.93. The stock’s fifty day moving average price is $18.50 and its 200-day moving average price is $13.34.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. The firm had revenue of $13.58 million during the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 60.99%. As a group, analysts expect that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the sale, the chief financial officer owned 37,592 shares in the company, valued at $472,155.52. This trade represents a 14.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Nurix Therapeutics

Institutional investors have recently modified their holdings of the stock. Wexford Capital LP purchased a new stake in shares of Nurix Therapeutics in the third quarter valued at approximately $41,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock worth $93,000 after buying an additional 1,970 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after buying an additional 3,475 shares during the period. Velan Capital Investment Management LP bought a new position in shares of Nurix Therapeutics during the 2nd quarter worth $114,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Nurix Therapeutics during the third quarter valued at $100,000.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Royal Bank of Canada raised its price target to $30 and assigned an “outperform” rating, implying substantial upside vs current levels. Benzinga
• Positive Sentiment: Analyst confirmations: BTIG reaffirmed a “buy” rating with a $30 target, and Needham reaffirmed a “buy” with a $26 target — both signal continued analyst confidence in share appreciation. Benzinga
• Positive Sentiment: Clinical & corporate update: Nurix began dosing first patients in the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL, presented supportive Phase 1 data at ASH 2025 (reported 83% ORR and 22.1‑month PFS), disclosed differentiated preclinical data for IRAK4 degrader GS‑6791 with Gilead, and ended the quarter with ~$592.9M in cash and marketable securities — items that materially improve execution and runway prospects. Corporate Update
• Neutral Sentiment: Quarterly results were mixed: NRIX reported a $0.82 loss per share, slightly better than consensus (-$0.86) and revenue of $13.58M vs. ~$13.41M expected — a modest beat on the headline numbers, but the company remains unprofitable with large negative margins. Press Release
• Negative Sentiment: Conflicting coverage: Zacks ran a headline framing the quarter as a loss that “misses revenue estimates,” which may create investor confusion despite the company-reported slight revenue beat — such mixed messaging can pressure the stock near earnings. Zacks

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.